Project CBD has published its in-depth Primer on Cannabinoid-Drug Interactions for health professionals, patients, and public policy-makers.
Study: Marijuana use and short-term outcomes in patients hospitalized for acute myocardial infarction
The aim of this retrospective study was to quantify short-term outcomes in marijuana-using and non-using patients hospitalized with AMI.
Study Shows Sharp Decline of Opiates Dispensed to Medicaid Recipients In States Regulating Medical Marijuana
New study published in the Journal of the American Medical Association finds a sharp decline of opiate doses dispensed to Medicaid recipients annually in regulation states
New study concludes that opiates dispensed to Medicare Part D subscribers dropped by an average of 3.6% or 3.742 million daily doses per year on average.
As lawmakers deliberate about the potential for a New Jersey cannabis program, closing the state’s budget gap is one of many advantages worth considering. Upon the release of its White…
Cannabidiol (CBD) isolates are suddenly getting a lot of attention in the scientific and medical communities and rave reviews by patients. But what are they exactly? By now, most people…
Researchers conducting a study on cannabis as a treatment for PTSD are seeking U.S. Military veterans to participate in a controlled clinical trial.
ECS Dysregulation In Autism Spectrum Disorders: Correlation between Inflammation & Neuro-Immune Alterations
Endocannabinod Signal Dysregulation in Autism Spectrum Disorders: A Correlation Link between Inflammatory State and Neuro-Immune Alterations Abstract Several studies highlight a key involvement of endocannabinoid (EC) system in autism pathophysiology.…
St George’s, University of London Department of Oncology shows evidence that cannabinoids kill leukemia cells when combined with chemotherapy.
New study conducted by Dr. Saul Garza Morales of Mexico concludes with results showing effectiveness of RSHO-X CBD treating childhood epilepsy.
As the first comprehensive study to be conducted by a Federally sanctioned institution, the NAS study has potential to expose the fallacy of the classification of cannabis as a Schedule 1 controlled substance.
This study indicates likelihood that autocatalytic inflammatory response within nerve cells can be blocked by the activation of cannabinoid receptors.